We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Optimum Platelet Inhibition After Coronary Bypass Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00262275
Recruitment Status : Completed
First Posted : December 6, 2005
Last Update Posted : January 22, 2016
Information provided by (Responsible Party):
Papworth Hospital NHS Foundation Trust

Brief Summary:
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Drug: Aspirin, Clopidogrel Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel
Study Start Date : July 2002
Actual Primary Completion Date : July 2004

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.

Exclusion Criteria:

Preoperative exclusion criteria:

  • patients who are have not stopped aspirin 7 days prior to surgery
  • patients on concomitant NSAIDS
  • patients with a previous history platelet disorders, splenectomy or haematological disorders
  • patients with aspirin induced asthma
  • patients with any contraindications to aspirin (GI bleed)
  • patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
  • Women of childbearing potential
  • Patients of less than 18 years
  • If informed consent cannot be obtained
  • If for any reason the consultant surgeon or anaesthetist deems it to be appropriate

Operative exclusion criteria:

• Concomitant procedures

Postoperative exclusion criteria:

  • patients who receive platelet transfusion
  • patients who receive NSAIDS
  • requirement for intra aortic balloon pump support
  • failure of extubation within 24 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262275

Layout table for location information
United Kingdom
Papworth Hospital
Cambridge, United Kingdom, CB3 8RE
Sponsors and Collaborators
Papworth Hospital NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Eric Lim, MB ChB, MSc, MRCS Papworth Hospital NHS Foundation Trust
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Papworth Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT00262275    
Other Study ID Numbers: LREC 01/624
First Posted: December 6, 2005    Key Record Dates
Last Update Posted: January 22, 2016
Last Verified: January 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents